Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytoto...

por Bellone, S, Roque, D, Cocco, E, Gasparrini, S, Bortolomai, I, Buza, N, Abu-Khalaf, M, Silasi, D-A, Ratner, E, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2012

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab

por Todeschini, P, Cocco, E, Bellone, S, Varughese, J, Lin, K, Carrara, L, Guzzo, F, Buza, N, Hui, P, Silasi, D-A, Ratner, E, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2011

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

por Schwab, C L, Bellone, S, English, D P, Roque, D M, Lopez, S, Cocco, E, Nicoletti, R, Bortolomai, I, Bonazzoli, E, Ratner, E, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Santin, A D
Publicado 2014

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma

por Cocco, E, Hu, Z, Richter, C E, Bellone, S, Casagrande, F, Bellone, M, Todeschini, P, Krikun, G, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Buza, N, Pecorelli, S, Lockwood, C J, Santin, A D
Publicado 2010

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer

por Cocco, E, Bellone, S, El-Sahwi, K, Cargnelutti, M, Casagrande, F, Buza, N, Tavassoli, F A, Siegel, E R, Visintin, I, Ratner, E, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2009

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

por El-Sahwi, K, Bellone, S, Cocco, E, Cargnelutti, M, Casagrande, F, Bellone, M, Abu-Khalaf, M, Buza, N, Tavassoli, F A, Hui, P, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2010

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy

por Bellone, S, Tassi, R, Betti, M, English, D, Cocco, E, Gasparrini, S, Bortolomai, I, Black, J D, Todeschini, P, Romani, C, Ravaggi, A, Bignotti, E, Bandiera, E, Zanotti, L, Pecorelli, S, Ardighieri, L, Falchetti, M, Donzelli, C, Siegel, E R, Azodi, M, Silasi, D-A, Ratner, E, Schwartz, P E, Rutherford, T J, Santin, A D
Publicado 2013